



107 Rec'd PCT/PT0 0.5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Kaveri et al.

Atty. Docket No. TJK/209

Serial No. 10/031,938

Group Art Unit:

Filed: January 22, 2002

Examiner:

Title: CATALYTIC ANTI-FACTOR VIII ALLO-ANTIBODIES

Assistant Commissioner of Patents

Washington, D.C. 20231

Sir:

TRANSMITTAL LETTER

TECH CENTER 1600/2000 In response to the Notice of Defective Response Action dated December 31, 2002, enclosed are the following:

- 1. Second Preliminary Amendment;
- 2. Computer Disk; and
- Check for \$618.00 for additional claims which were not initially paid for with the 3. initial filing (58 total claims originally paid for, 8 independent claims originally paid for - Fee for 11 additional claims @ \$18.00 = \$198.00 - Fee for 5 additional Independent claims @ \$84.00 = \$420.00);
- 4. Duplicate Copy of Notification of Defective Response; and
- 5. Stamped, self-addressed receipt postcard.

Please charge any additional fees which include extension fees if any to Deposit Account

No. 23-2126. An extra copy is enclosed.

ctfally submitted.

A. Keefer Registration No. 35,567

02/07/2003 LLANDGRA 00000055 10031938

01 FC:1615 02 FC:1614

198.00 OP 420.00 DP CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on // 38/20

Mindy L. Fitch



Kaveri et al. 10/031,938

CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Kaveri et al.) CATALYTIC ANTI-FACTOR VIII ALLO- ANTIBODIES	
Serial No.:) Attorney Docket: 7) Group Art Unit:)) Examiner:	RECEIVED APR 2 4 2003
	<u>CERTIFI</u>	ICATE OF MAILING	TECH CENTER 1600/2900
	the U.S. Postal Service as f	first class mail in an envelope at for Patents, Washington, D.C., 2003. Jimothy J. Reefer Attorney for Applicants Reg. No. 35567	addressed
	Date of Signature:	// W , 2003	
Assistant Co	emmissioner for Patents	,	
Washington,	, D.C. 20231		

SECOND PRELIMINARY AMENDMENT

IN THE SPECIFICATION:

On page 6, lines 17-32, continuing through to page 7, lines 1-10, please delete the existing paragraph and replace it with the following paragraph:

Hence, according to a third aspect, the present invention provides an anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor. Advantageously, this inhibitor is

01/27/03 1:16 PM Doc. No.: 1154664